1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Review Pathways

Breakthrough Designation Rescissions: Who Might US FDA Drop Next?

 
• By Bridget Silverman

Our chart details the pipeline candidates who might lose the coveted status as treatment paradigms change and trial results come in.

Car rear view system monitor reverse video camera
Even if a development-stage product loses Breakthrough designation from the US FDA, it's regulatory progress isn't necessarily going in reverse.

Being told you aren't special isn't particularly fun, but it's not the end of the world either, as anyone who has gone through a bad breakup can attest. Still, no one likes getting dumped, and given that Tonix Pharmaceuticals Holding Corp.’s PTSD therapy Tonyma and Trevena Inc.’s novel pain drug Olinvo just had to break up with their Breakthrough Therapy Designations (BTDs), the Pink Sheet is thinking about some other pipeline candidates that the US FDA might soon be telling, "It's not you, it's me."

It's actually trial results and changes to existing treatment paradigms, rather than FDA's shifting sentiments, that cause a candidate to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

UK MHRA: Bacteriophage Developers Wanted ‘More Clarity’ On UK Framework

 
• By Eliza Slawther

Julian Beach, interim executive director of healthcare quality and access at the UK drug regulator, the MHRA, tells the Pink Sheet how the agency is responding to increased efforts to develop bacteriophage therapies.

User Fee-Funded Staff Would Drop In FY 2026 US FDA Budget

 
• By Derrick Gingery

The reductions across medical product programs in the agency’s budget request include hundreds of positions funded by user fees, which may foreshadow its upcoming user fee restructuring strategy.

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 
• By Eliza Slawther

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

US FDA’s Prasad: ‘We Will Always Embrace Surrogate Endpoints’

 
• By Sarah Karlin-Smith

The new CBER director, once best known in the pharma world for criticizing accelerated approval, committed to expediting cancer drugs with surrogate endpoints.

More from Pathways & Standards

MHRA Backs Bacteriophage Innovation To Fight Antimicrobial Resistance

 
• By Eliza Slawther

The UK regulator wants to help companies to develop bacteriophages for the treatment of infections. Its first guidance on this topic offers advice to researchers and sets out the regulatory requirements they will need to meet.

US FDA Cell-Gene Therapy Head Says Agency Has Revived Stalled Programs

 
• By Sarah Karlin-Smith

CBER's Nicole Verdun wants rare disease sponsors with stalled treatments to circle back because the FDA's evolved thinking on clinical trial designs may offer another opportunity for cast away products.

FDA’s FY 2026 Budget Request Lacks New Policy Proposals

 
• By Sue Sutter

The White House requested $6.8bn for the FDA, down 3.9% from the current funding level, but does not propose any legislative changes. In previous years, the agency used the budget process to seek statutory fixes specific to generic drugs and shortages.